
Quick Links
You are about to leave www.astellas.com and enter a third-party website. Astellas is not responsible for the content or services on the third-party website.
Would you like to continue?
Astellas is committed to providing timely and accurate information about our business, science and products. This section offers local resources for investors, journalists and media professionals. Global news and resources can be viewed here. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
–八篇摘要,涵盖FLT3突变阳性的急性髓性白血病、患者治疗偏好以及在难治性血液肿瘤上的临床应用。...
Read more about 在欧洲血液学协会年会(EHA2021),八篇新研究成果反映了安斯泰来对急性髓性白血病的承诺
安斯泰来3月提交的新药申请是用于治疗经抗癌药物治疗后进展的局部晚期或转移性尿路上皮癌...
恩扎卢胺是目前唯一一款获得欧盟委员会批准治疗三类晚期前列腺癌的口服药物。...
–在中国与其他国家进行的三期确证性临床试验,因预设的期中分析取得积极成果而提前结束。...
Read more about 安斯泰来用于治疗携带FLT3突变的复发性或难治性急性髓系白血病成人患者的富马酸吉瑞替尼片在COMMODORE试验中达到总生存期的主要终点
2021年2月19日,东京——安斯泰来制药集团(TSE:4503,总裁兼首席执行官:安川健司博士,“安斯泰来”)今天宣布fezolinetant的关键性III期临床试验SKY...
Read more about 安斯泰来宣布非激素类药物Fezolinetant治疗绝经女性血管舒缩症状的两项全球关键性III期临床试验取得积极结果
